Nectar Lifesciences Limited

NSE: NECLIFE · Unclassified

₹10.05-1.47%06 Nov 2026

One-off: net profit of ₹-176.01 cr in SEP '25 includes ₹-175.68 cr from discontinued operations (a business the company is exiting); continuing operations earned ₹-0.33 cr. Trailing-twelve-month figures (EPS, P/E, ROE) include it.

Ask the data

Instant answers about Nectar Lifesciences Limited — computed from its filings, no language model

Market cap₹195 cr

Current price₹10.05

High / Low₹22 / ₹9

P/E—

P/B0.34

Book value₹30.0

ROE-42.1%

ROCE1.9%

Debt / equity0.00

Dividend yield—

EPS (TTM)₹-12.61

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 7 periods

	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	2,367	1,544	1,669	1,525	1,686	1,673	0
EBITDA	220	110	159	54	153	-26	-61
Operating margin	9.3%	7.1%	9.5%	3.5%	9.1%	-1.6%	—
Interest	126	112	79	79	87	75	36
Depreciation	61	60	57	59	61	62	0
Profit before tax	37	-85	34	-42	18	-162	-88
Tax	6	-12	9	-18	13	-48	-31
Net profit	32	-73	0	0	0	-114	-293
EPS ₹	1.42	-3.27	1.12	-1.08	0.22	-5.07	-13.40
Operating cash flow	—	—	95	134	225	169	-349
Capex	—	—	25	30	29	44	12
Dividend paid	—	—	0	0	0	0	0
Total assets	—	—	—	2,189	2,191	2,047	622
Equity	—	—	—	1,065	1,069	956	582

Quarterly performance

last 29 quarters · ₹ crore

showing latest 8 of 29 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
Revenue	575	579	648	565	390	428	378	349	385	365	443	476	403	389	344	389	394	398	452	441	359	428	455	431	281	5	0	0	0
Operating profit	62	48	56	54	17	31	33	29	35	27	47	49	42	-7	1	18	36	27	42	48	40	43	45	-154	-62	-1	-2	-59	-28
Operating margin	10.8%	8.3%	8.6%	9.6%	4.3%	7.4%	8.7%	8.4%	9.2%	7.5%	10.5%	10.3%	10.4%	-1.9%	0.4%	4.7%	9.0%	6.7%	9.3%	11.0%	11.1%	10.1%	9.8%	-35.8%	-22.1%	-20.8%	—	—	-277000.0%
Other income	2	1	1	0	1	1	1	1	5	5	1	1	0	11	13	18	0	11	0	1	1	1	1	0	0	1	1	8	3
Interest	31	33	31	31	28	28	31	26	26	18	18	17	21	21	17	20	18	21	25	24	20	20	17	18	19	0	30	6	0
Depreciation	16	14	15	15	15	15	15	15	14	14	14	14	15	15	15	15	15	15	15	15	15	16	16	16	17	0	0	0	0
Profit before tax	16	3	10	8	-26	-11	-12	-36	0	0	15	18	6	-32	-18	2	3	2	2	11	5	9	13	-188	-97	-1	57	-57	-25
Tax	3	0	2	1	-9	-4	-4	5	-1	-1	5	6	2	-10	-8	-2	1	1	1	11	2	3	5	-58	-34	-0	-11	-20	-9
Net profit	14	2	8	7	-17	-7	-8	-41	0	0	0	0	0	-22	-9	0	0	1	2	0	0	6	0	-130	-63	-176	14	-68	-15
EPS ₹	0.61	0.11	0.37	0.33	-0.75	-0.33	-0.36	-1.83	0.08	0.08	0.43	0.52	0.17	-1.00	-0.41	0.16	0.08	0.05	0.07	0.03	0.13	0.25	0.35	-5.80	-2.82	-7.84	0.64	-3.38	-0.79
Revenue YoY	—	—	—	—	-32.3%	-26.0%	-41.7%	-38.2%	-1.2%	-14.8%	17.2%	36.5%	4.7%	6.6%	-22.3%	-18.4%	-2.2%	2.4%	31.4%	13.5%	-8.8%	7.6%	0.6%	-2.4%	-21.9%	-98.8%	-100.0%	-100.0%	-100.0%
Profit YoY	—	—	—	—	-223.4%	-398.4%	-198.2%	-652.2%	—	—	—	—	—	—	—	—	—	—	—	—	—	449.0%	-100.0%	—	—	-3243.0%	—	—	—

Earlier results (standalone, Sep '07 – Mar '19)

₹ crore · from BSE, before the NSE XBRL filings begin

Nectar Lifesciences Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†	FY18†	FY19†
Revenue	1,063	1,312	1,626	1,638	1,644	1,676	1,669	1,947	2,785
Operating profit	233	245	290	289	267	275	225	236	264
Operating margin	21.9%	18.7%	17.8%	17.6%	16.2%	16.4%	13.5%	12.1%	9.5%
Other income	14	12	16	12	20	6	22	6	6
Interest	77	104	115	138	126	122	117	115	148
Depreciation	46	59	76	84	77	85	62	64	63
Profit before tax	125	95	115	78	85	73	67	63	59
Tax	23	14	29	16	18	13	12	10	11
Net profit	102	80	86	62	66	59	55	52	47

Quarters

showing latest 8 of 44 periods

	SEP '07†	DEC '07†	JUN '08†	SEP '08†	DEC '08†	JUN '09†	SEP '09†	DEC '09†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†	SEP '18†	DEC '18†	MAR '19†
Revenue	194	173	185	237	135	193	254	261	182	217	323	341	211	293	412	397	394	495	369	368	345	442	391	461	382	394	444	424	408	397	397	475	354	415	443	456	342	480	532	594	533	722	731	799
Operating profit	31	30	37	48	26	45	50	55	45	54	68	66	45	57	75	68	60	71	72	87	58	76	80	75	66	72	73	56	71	74	73	58	57	62	69	37	53	65	68	51	60	64	66	74
Operating margin	16.0%	17.5%	19.9%	20.1%	19.4%	23.1%	19.5%	21.2%	24.6%	25.0%	21.2%	19.2%	21.2%	19.6%	18.2%	17.3%	15.3%	14.3%	19.5%	23.6%	16.8%	17.3%	20.3%	16.2%	17.2%	18.4%	16.4%	13.2%	17.3%	18.6%	18.3%	12.2%	16.1%	14.8%	15.5%	8.1%	15.4%	13.5%	12.8%	8.6%	11.3%	8.8%	9.0%	9.3%
Other income	5	2	1	1	1	0	1	1	0	0	0	13	0	5	4	4	4	4	4	4	4	4	2	1	2	3	2	13	1	1	2	1	1	1	2	17	1	1	2	1	1	1	2	2
Interest	8	10	8	12	13	16	11	14	13	13	16	35	20	21	25	38	25	28	28	35	26	39	40	33	28	35	35	27	27	31	30	34	29	29	34	26	27	28	31	30	30	44	36	39
Depreciation	4	4	6	9	8	9	10	10	11	11	12	11	12	16	17	14	18	19	19	20	21	21	21	21	19	19	19	19	22	22	22	20	15	15	15	17	15	16	16	16	16	16	17	15
Profit before tax	24	18	24	27	6	20	29	32	21	29	41	33	13	25	37	20	22	28	29	36	15	20	21	22	20	21	21	22	23	22	22	6	15	19	22	11	12	22	23	6	15	6	14	23
Tax	1	0	0	0	0	0	0	0	5	5	11	1	2	3	4	5	6	6	7	10	4	5	4	3	4	4	4	6	5	5	4	-1	2	3	4	3	1	3	4	2	2	1	3	5
Net profit	23	18	24	27	6	20	29	32	16	24	30	32	11	21	32	15	16	23	21	26	11	15	17	19	16	16	17	17	17	17	17	7	12	16	18	9	10	19	19	4	13	5	11	17
EPS ₹	15.55	12.07	15.83	17.87	0.37	1.34	1.91	2.11	0.70	0.86	1.35	1.42	0.50	0.95	1.44	0.69	0.71	1.01	0.96	1.14	0.49	0.68	0.76	0.83	0.72	0.73	0.75	0.75	0.78	0.77	0.78	0.32	0.55	0.72	0.81	0.38	0.46	0.84	0.85	0.17	0.59	0.24	0.50	0.78
Revenue YoY	—	—	—	22.2%	-22.2%	3.9%	7.3%	93.4%	-5.5%	-14.6%	23.9%	—	16.1%	34.8%	27.5%	16.3%	86.5%	69.3%	-10.3%	-7.3%	-12.5%	-10.8%	6.0%	25.3%	10.7%	-10.8%	13.6%	-8.1%	6.8%	0.7%	-10.6%	12.1%	-13.1%	4.5%	11.6%	-3.9%	-3.7%	15.8%	19.9%	30.2%	56.0%	50.5%	37.6%	34.4%
Profit YoY	—	—	—	17.6%	-68.6%	-15.1%	6.9%	469.0%	-23.3%	-17.0%	-6.0%	—	-28.4%	-11.8%	7.2%	-51.5%	42.9%	5.9%	-33.8%	66.0%	-30.9%	-32.7%	-20.1%	-27.1%	46.7%	8.2%	-1.5%	-10.6%	7.1%	5.5%	3.1%	-57.2%	-29.4%	-6.9%	4.3%	20.0%	-15.5%	17.1%	4.7%	-54.7%	27.1%	-71.4%	-40.4%	347.6%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 26 periods

	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
ROE	—	—	—	—	—	—	—	—	—	—	-2.1%	-3.0%	-3.0%	-3.0%	-0.8%	0.2%	0.2%	0.2%	0.7%	0.5%	-13.0%	-19.6%	-51.5%	-49.5%	-50.3%	-42.1%
ROCE	—	—	—	—	—	—	—	—	—	—	4.5%	2.8%	2.0%	1.7%	3.7%	5.2%	6.2%	6.4%	6.8%	6.9%	-5.7%	-12.3%	-18.6%	-13.8%	-7.3%	1.9%
Net margin	1.3%	0.1%	-0.4%	-1.4%	-4.7%	-3.7%	-3.3%	-2.7%	0.0%	0.0%	-1.3%	-2.0%	-2.1%	-2.1%	-0.5%	0.2%	0.2%	0.2%	0.4%	0.3%	-7.4%	-11.8%	-31.5%	-49.6%	-102.5%	-4891.4%
EBITDA margin	9.3%	8.0%	7.8%	7.7%	7.1%	8.4%	8.5%	9.0%	9.5%	9.8%	7.6%	5.3%	3.5%	3.1%	5.4%	7.5%	9.1%	9.5%	10.3%	10.5%	-1.6%	-8.0%	-14.7%	-30.6%	-43.2%	-1780.2%
Debt / equity	—	—	—	—	—	—	—	—	—	—	0.74	0.74	0.71	0.71	0.64	0.64	0.59	0.59	0.58	0.58	0.61	0.61	0.64	0.64	0.00	0.00
Interest coverage	1.30	0.96	0.85	0.65	0.24	0.47	0.53	0.77	1.43	1.53	1.09	0.66	0.47	0.40	0.85	1.10	1.21	1.22	1.31	1.46	-1.17	-2.59	-4.09	-2.43	-0.78	0.30
Asset turnover	—	—	—	—	—	—	—	—	—	—	0.75	0.70	0.70	0.69	0.71	0.76	0.77	0.75	0.77	0.77	0.82	0.78	0.65	0.39	0.46	0.01

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 8 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26
Share capital	22	22	22	22	22	22	22	19
Other equity / reserves	1,047	1,042	1,045	1,047	1,055	934	694	563
Total equity	1,069	1,065	1,067	1,069	1,078	956	717	582
Borrowings	790	754	681	636	629	582	459	0
Current liabilities	944	891	885	973	997	1,022	713	26
Non-current liabilities	275	234	191	149	108	70	13	9
Total assets	2,288	2,189	2,143	2,191	2,183	2,047	1,815	622
Property, plant & equipment	644	613	594	590	576	577	28	103
Capital work-in-progress	86	78	78	66	57	57	—	0
Investments	0	1	1	1	1	1	1	13
Inventories	685	673	649	709	749	690	3	0
Receivables	334	287	308	387	387	354	61	0
Cash & equivalents	14	18	20	20	18	19	6	0

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	95	134	225	169	-349
Cash from investing	17	52	-17	-42	1,208
Cash from financing	-119	-186	-205	-128	-767
Capex	25	30	29	44	12
Free cash flow	70	104	195	126	-361
Dividends paid	0	0	0	0	0

Where the assets sit

Mar '26 · ₹ crore

Fixed assets (PPE)

₹103 cr17%

Investments

₹13 cr2%

Inventories

₹0 cr0%

Other assets

₹505 cr81%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Nectar Lifesciences Limited	195	10.05	—	0.34	-42.1%

StoxGud checklist: Bearish setup · 2/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-5.1%

6 months-25.9%

1 year-36.2%

3Y CAGR-25.3%

5Y CAGR-17.8%

10Y CAGR-12.0%

50-day avg₹11.00

200-day avg₹11.66

RSI (14)41

FAQs

What is the share price of Nectar Lifesciences Limited?

Nectar Lifesciences Limited (NECLIFE) closed at ₹10.05 on NSE on 06 Nov 2026.

What is the market cap of Nectar Lifesciences Limited?

₹195 crore at the latest close.

How fast is Nectar Lifesciences Limited growing?

Nectar Lifesciences Limited: Latest-quarter revenue is down 100.0% year on year.

How profitable is Nectar Lifesciences Limited?

On a trailing-twelve-month basis return on equity is -42.1%, return on capital employed 1.9%, operating margin -1,780.2%, net margin -4,891.4%.

How much debt does Nectar Lifesciences Limited have?

Nectar Lifesciences Limited is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹0 cr (balance sheet of 2026-03-31). Operating profit covers interest 0.3 times.

Financials parsed from Nectar Lifesciences Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '19, annual from FY20, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.